Health & Biotech
At Paradigm, we firmly believe that the key to addressing unmet medical needs lies in unlocking the potential of forgotten compounds. Our strategy is to take unconventional routes to develop safe and effective treatments for clinical conditions that lack viable options.
Our current primary focus is the development of injectable pentosan polysulfate sodium (iPPS/Zilosul®), for the treatment of osteoarthritis (OA). An ability to provide a safe an effective treatment for OA is a blockbuster market opportunity as there are limited therapeutic solutions available. We’ve charged ahead into global phase 3 trials, addressing the core components of the disease: inflammation, pain, and regeneration. Zilosul® possesses the remarkable potential to provide long-term pain reduction and modify the underlying course of this debilitating disease.
With our headquarters in Melbourne, Australia, and strategic offices in the European Union and the United States, Paradigm is poised to make a global impact. Our international presence reflects our commitment to delivering ground breaking treatments to patients worldwide.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: The robots are taking over biotech stock selection
Health & Biotech
Paradigm raises $16m for phase III trial of knee osteoarthritis treatment
Health & Biotech
Health Check: Biotech’s forgotten tortoises pick up the pace as sector emerges from two-year slump
Health & Biotech
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns
News
ASX November Winners: The 50 best stocks as ASX 200 reached record high
News
Closing Bell: Another record for ASX as Pro Medicus’ big contract win lifts healthcare sector
Health & Biotech
Paradigm clear for phase 3 following US FDA review
Health & Biotech
Health Check: Biotech double-banger breaks the IPO drought
Health & Biotech
Health Check: Painchek strives to Make American Aged Folk Comfortable Again
Health & Biotech
Health Check: Sonic Healthcare is cashed up and ready to boom as earnings improve
Health & Biotech
Health Check: Which biotech boards are at risk of a ‘second strike’?
Health & Biotech
ASX Quarterly Health Wrap: Action for Dimerix Phase 3 kidney trial
News
Closing Bell: ASX dips as AGL stalls; Talga skyrockets after Sweden approves graphite mine
News
Market Highlights: Gold hits new highs while Meta misses the mark; and 5 ASX small caps to watch
Health & Biotech
Biocurious: Cracking the code on Paradigm’s valuation enigma
Health & Biotech
Health Check: Just the news we ‘kneed’ as Paradigm aims to kick-start US osteo trial
Health & Biotech